Femasys Inc.
Organization details
- Legal name
- Femasys Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Suwanee
- Headquarters state / province
- Georgia
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FEMY
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001339005
- EIN
- 11-3713499
Board of directors
-
Alistair Milnes · DirectorSince 2023
-
Anne Morrissey · DirectorSince 2023
-
Charles Larsen · DirectorSince 2023
-
Edward R. Uzialko · DirectorSince 2023
-
John Hunnewell Moorhead Jr. · DirectorSince 2026
- Since 2023
-
Kathy Lee-Sepsick · Director · Chief Executive OfficerSince 2023
-
Keith J. Kendall · DirectorSince 2023
-
Kenneth D. Eichenbaum · DirectorSince 2026
-
Wendy Perrow · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
93.3%
-
95.8%
Board connections
2 of this board's directors also sit on 5 other boards. 3 are in the same sector.
- via Joshua Silverman
-
InfuSystems Holdings Inc. Same sectorvia Kenneth D. Eichenbaum
-
PharmaCyte Biotech Inc. Same sectorvia Joshua Silverman
-
Q/C Technologies Inc. Same sectorvia Joshua Silverman
- via Joshua Silverman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $134,000
- 5 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Canning John Charles Officer (Chief Operating Officer) | Open-market purchase | +4,375 | $3.20 | $14,000 |
| Aug 7, 2026 | Elefant Dov Officer (Chief Financial Officer) | Open-market purchase | +15,625 | $3.20 | $50,000 |
| Aug 7, 2026 | Kathy Lee-Sepsick Director, Officer (Chief Executive Officer) | Open-market purchase | +15,625 | $3.20 | $50,000 |
| Aug 7, 2026 | Sipos Jeremy Alexander Officer (Chief Technology Officer) | Open-market purchase | +3,125 | $3.20 | $10,000 |
| Aug 7, 2026 | Mifek Jeffrey Gerald Officer (Chief Clinical-Medical Affairs) | Open-market purchase | +3,125 | $3.20 | $10,000 |
| Aug 27, 2025 | Elefant Dov Officer (Chief Financial Officer) | Discretionary transaction | +38,828 | — | — |
| Aug 27, 2025 | Kathy Lee-Sepsick Director, Officer (Chief Executive Officer) | Discretionary transaction | +48,535 | — | — |
| Jun 2, 2025 | Charles Larsen Director | Discretionary transaction | +24,510 | $1.02 | $25,000 |
| Jun 2, 2025 | Currie Daniel Scott Officer (Chief Operating Officer) | Discretionary transaction | +19,608 | $1.02 | $20,000 |
| Jun 2, 2025 | Elefant Dov Officer (Chief Financial Officer) | Discretionary transaction | +19,608 | $1.02 | $20,000 |
| Jun 2, 2025 | Kathy Lee-Sepsick Director, Officer (Chief Executive Officer) | Discretionary transaction | +34,314 | $1.02 | $35,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Femasys Inc.
Who is the CEO of Femasys Inc.?
Kathy Lee-Sepsick is Femasys Inc.'s Chief Executive Officer.
How many directors are on Femasys Inc.'s board?
Femasys Inc.'s board has 10 directors: Alistair Milnes, Anne Morrissey, Charles Larsen, Edward R. Uzialko, John Hunnewell Moorhead Jr., Joshua Silverman, Kathy Lee-Sepsick, Keith J. Kendall, Kenneth D. Eichenbaum and Wendy Perrow.
Are Femasys Inc. insiders buying or selling shares?
Over the last 12 months, Femasys Inc. insiders bought $134,000 of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="femasys-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.